Asset
HYPERICIN
Revenue
No revenue reported in loaded filings.
Clinical trials (5)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06470451 | phase3 | terminated | 2025-01-07 | 2026-05-22 | Soligenix | Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL |
| NCT02448381 | phase3 | completed | 2015-12-01 | 2020-06-01 | Soligenix | FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides) |
| NCT06149247 | phase2 | completed | 2023-12-05 | 2024-05-31 | Soligenix | HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL |
| NCT05380635 | phase2 | completed | 2022-05-09 | 2022-08-16 | Soligenix | PK and ECG Determinations Following 8 Weeks of HyBryte Treatment for Cutaneous T-Cell Lymphoma |
| NCT05442190 | phase2 | completed | 2022-12-14 | 2025-10-22 | Soligenix | Topical SGX302 for Mild-to-Moderate Psoriasis |
FDA applications (0)
This company has no applications containing this asset.